Author: Edwin Bemmel, AVP, Research Grants & Contracts
Effective November 17th, 2025, all open-ended clinical trials in Compass with end dates ten years or more from the execution date will have their end dates reduced by five years. Compass will be updated accordingly. Studies with adjusted end dates prior to January 1, 2026, are exempt from this change. All new open-ended studies will be assigned end dates five years from execution. Upon request, extended end dates for expired awards may be granted by RGC for up to five years, once justified.
Rationale:
Industry-funded clinical trials often use open-ended agreements to minimize administrative burden. Internal controls in Compass require end dates for all awards, so these trials are typically set up with a ten-year end date. This practice can leave studies open long after clinical activities have ended. Reducing the default end date to five years will allow active studies to be extended as needed, while minimizing the duration that inactive studies remain open.
Background:
This change is intended to improve the financial management of industry-funded clinical trials by shortening the default duration for open-ended studies from ten years to five years.
This change is intended to improve the financial management of industry-funded clinical trials by shortening the default duration for open-ended studies from ten years to five years.